Company: BDRX
Filing Date: 2025-12-08
Form Type: F-1/A
Source: 0001214659-25-017719
Chunk: 49

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-08
Form: F-1/A
Chunk 49
---
 and maintain such tolimidone patents. The Melior License Agreement may be terminated
by Melior if we fail to meet various development diligence obligations.

In connection with the License
Agreement, on November 22, 2023, Melior and Bukwang entered into an amendment to the license agreement with Bukwang, or the Bukwang License.
Under the amendment, the Bukwang License terminated in its entirety and Bukwang transferred to Melior all rights, titles and interests
to certain INDs, know-how and data, and patents relating to tolimidone.

Under the Bukwang Amendment,
Melior and Bukwang entered into a royalty agreement pursuant to which Bukwang shall be entitled to 50% of all payments Melior receives
under the License Agreement, including: (i) 50% of the equity issued by us under the License Agreement, and (ii) 50% of the royalties
that we will pay to Melior. Further, under the royalty agreement, Bukwang will pay to Melior $100,000 in consideration for Melior’s
waiver of Bukwang’s obligation to pay patent costs pursuant to the Bukwang License, and Melior will take back responsibility for
all tolimidone patent prosecution and maintenance costs.

Additional Information

Additional information regarding the Company, including
our intellectual property, sales and marketing, research and development capabilities, competitors and regulatory environment, is set
forth in our Annual Report on Form 20-F for the year ended December 31, 2024 and the other documents we incorporate by reference herein.

| 31 |

<div align='center'>PRINCIPAL SHAREHOLDERS</div>

The following table sets forth information,
to our knowledge, as of December 1, 2025, regarding the beneficial ownership of Ordinary Shares (including those represented by Depositary
Shares), including:

| · | each person, or group of affiliated persons, that is known by us to be a beneficial owner of 5% or more   
 of Ordinary Shares (based on information in our share register and information provided by such persons); |

| · | each member of our Board of Directors; |

| · | each member of our senior management; and |

| · | all members of our Board of Directors and our senior management, taken as a group. |

Beneficial
ownership of shares is determined under rules of the SEC and generally includes any shares
over which a person exercises sole or shared voting or investment power. Except as noted
by footnote